Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04452955 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
A Phase 2 study of Solid Tumor, sponsored by Intra-IMMUSG Pte.
- Active
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 5
- Study locations
NCT04452955: Active Phase 2 study of Solid Tumor, sponsored by Intra-IMMUSG Pte.
NCT04452955 is a Phase 2 study of Solid Tumor that is active but no longer recruiting, run by Intra-IMMUSG Pte. The registered enrollment target is 51 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (77% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04452955, a Phase 2 study of Solid Tumor, is active but no longer recruiting, sponsored by Intra-IMMUSG Pte.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multi-center, Phase 2, open-label, single dose level study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumor.
Primary Outcome
PFS is defined as the time from the initiation of study treatment to the date of disease progression as per RECIST v1.1 and iRECIST criteria.
Conditions Studied
Interventions
- BIOLOGICAL PRL3-zumab
Study Locations (5)
California
- St. Jude Medical Center - Fullerton
- The Angeles Clinic - Los Angeles
Arizona
- HonorHealth Research - Scottsdale
Kentucky
- Norton Healthcare - Louisville
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2020-12-12 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 2 |
What the registry record for NCT04452955 still lists
NCT04452955 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PRL3-zumab is the first listed.
NCT04452955 lists 5 locations in 4 states (California, Arizona, Kentucky).
Frequently Asked Questions
What is clinical trial NCT04452955 about?
NCT04452955 is a clinical study titled "A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors". This is a multi-center, Phase 2, open-label, single dose level study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumor.
What is the current status of trial NCT04452955?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2020-12-12. Estimated completion is 2026-03-01.
What conditions does trial NCT04452955 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT04452955?
The interventions under investigation include: PRL3-zumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04452955?
This trial is sponsored by Intra-IMMUSG Pte, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04452955 being conducted?
This trial has 5 study locations across Arizona, California, Kentucky, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04452955's enrollment target sits among peer trials
51 120th of 196 higher than 76 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
RECRUITING · Phase 2
-
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
RECRUITING · Phase 2
-
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI